Edition:
United States

Biotechnology & Medical Research

Page 1

Global Blood Therapeutics announces proposed public offering of common stock

4:01pm EST

Global Blood Therapeutics Inc : Global Blood Therapeutics announces proposed public offering of common stock . Says agreement to sell $75.00 million in shares of its common stock in a registered underwritten public offering . Intends to use net proceeds from offering for development relating to its lead product candidate GBT440 .In addition, GBT has granted underwriter a 30-day option to purchase up to $11.25 million in shares of its common stock.

BioTime reports pro forma gain on deconsolidation of OncoCyte subsidiary

6:45am EST

BioTime Inc : BioTime - Deconsolidation of Oncocyte's financial's from co's consolidated financial statements; co to report pro forma non-cash gain of about $56 million .BioTime Inc- amount of gain will be determined and recorded during quarter ending March 31, 2017.

Evotec says will issue 13.1 million new shares to Novo A/S

Thursday, 9 Feb 2017 03:34pm EST

Evotec Ag : Novo A/S becomes new long-term strategic shareholder in Evotec . It resolved on a capital increase from its authorised capital against cash . Evotec will issue 13.1 million new shares to Novo A/S .Novo A/S will invest eur 90.3 m to subscribe shares of evotec at a share price of eur 6.87 per share.

CERECOR ENGAGES SUNTRUST ROBINSON HUMPHREY TO ASSIST WITH REVIEW OF STRATEGIC ALTERNATIVES

Tuesday, 7 Feb 2017 09:32am EST

Cerecor Inc : CERECOR ENGAGES SUNTRUST ROBINSON HUMPHREY TO ASSIST WITH REVIEW OF STRATEGIC ALTERNATIVES . HAS INITIATED A PROCESS TO EXPLORE AND REVIEW A RANGE OF STRATEGIC ALTERNATIVES .SAYS STRATEGIC ALTERNATIVES THAT MAY BE EXPLORED OR EVALUATED AS PART OF THIS PROCESS INCLUDE AN ACQUISITION, MERGER, BUSINESS COMBINATION.

Ab-Biotics takes ownership of 10 pct stake in Access DX Laboratory

Thursday, 2 Feb 2017 12:01pm EST

AB-Biotics SA : Takes ownership of 10 percent of the newly created North American company Access DX Laboratory .Access DX Laboratory was created as part of restructuring process of Ab-Biotics' client Companion DX.

Qiagen NV Q4 SHR $0.04

Wednesday, 1 Feb 2017 04:05pm EST

Qiagen NV : Reports 2016 adjusted EPS $0.87 . Reports 2016 EPS $0.34 . Qtrly Earnings Per Share $0.04 . Qtrly adjusted EPS $0.15 . Qiagen reaffirms full-year 2017 outlook for 6-7% CER sales growth . Qiagen reports results for fourth quarter and full-year 2016 . Q4 sales $366.5 million versus I/B/E/S view $370.7 million .Reaffirms full-year 2017 outlook for adjusted EPS target before restructuring costs of $1.25-1.27 cer.

BRIEF-Qiagen Q4 adjusted eps $0.15

Wednesday, 1 Feb 2017 04:05pm EST

Corrects 6th and 7th bullet to say company reported, not expects 2016 adj. EPS of $0.87 and EPS of $0.34.Qiagen NV : Qiagen NV qtrly earnings per share $0.04 . Qiagen NV qtrly adjusted EPS $0.15 . Qiagen reaffirms full-year 2017 outlook for 6-7 pct CER sales growth . Reports results for fourth quarter and full-year 2016 . Q4 sales $366.5 million versus I/B/E/S view $370.7 million . Reports 2016 adjusted EPS $0.87 . Reports 2016 EPS $0.34 .Reaffirms full-year 2017 outlook for adjusted EPS target before restructuring costs of $1.25-1.27 CER.

Anhui Anke Biotechnology (Group) sees FY 2016 net profit up 11 pct to 25 pct

Friday, 27 Jan 2017 04:00am EST

Anhui Anke Biotechnology Group Co Ltd <300009.SZ> : Sees FY 2016 net profit to increase by 11 percent to 25 percent, or to be 26 million yuan to 29.3 million yuan . Says FY 2015 net profit was 23.4 million yuan .The reasons are turnaround of traditional coal mine business and transformation of subsidiary.

Biotest to sell US therapy business to ADMA Biologics Inc.

Monday, 23 Jan 2017 07:00am EST

Biotest AG : Biotest to sell US therapy business to ADMA Biologics, Inc. receiving approximately 50% of the shares of ADMA Biologics, Inc . As part of transaction, biotest will contribute 11.5 million euros ($12.34 million) in cash as well as a 14 million euros loan . EBIT of continued operations is expected to improve by approx. 30 million euros in fiscal year 2016 . In addition, Biotest will contribute up to 11.5 million euros towards a future capital increase of adma on equal terms as third party investors .Transaction is expected to close during first half of 2017.

Parexel International approved plan to restructure its operations on Jan. 6, 2017,

Monday, 9 Jan 2017 04:48pm EST

Parexel International Corp : Parexel international corp - on January 6, 2017, approved plan to restructure its operations - sec filing . Parexel international corp - restructuring initiative is company-wide . Parexel international - actions are expected to result in pre-tax charges in range of $25 - $35 million, all of which are anticipated to be cash expenditures . Parexel international-charges will include about $24 million to $32 million in employee separation costs and approximately $1 million to $3 million in other costs . Parexel international - expects to record a pre-tax charge in q3 of fiscal year ending june 30, 2017 in range of $20 million to $27 million . Co anticipates completing restructuring activities by end of fiscal year 2018 . Parexel international corp - expects charges to result in annual pre-tax savings of approximately $7 million to $10 million over course of fiscal year 2017 . Parexel international - expects to record remainder of charges to be incurred by end of fiscal year ending june 30, 2018 .Parexel international corp - expects charges to result in approximately $30 million to $40 million on an annualized basis when plans fully completed.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary